<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4068">
  <stage>Registered</stage>
  <submitdate>5/02/2013</submitdate>
  <approvaldate>5/02/2013</approvaldate>
  <nctid>NCT01785602</nctid>
  <trial_identification>
    <studytitle>Efficacy and Safety Study of QAW039 in the Treatment of Patients With Moderate to Severe Atopic Dermatitis.</studytitle>
    <scientifictitle>A Randomized, Double-blind, Placebo-controlled, Parallel Group Study Evaluating Efficacy and Safety of QAW039 in the Treatment of Patients With Moderate to Severe Atopic Dermatitis</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2012-005321-78</secondaryid>
    <secondaryid>CQAW039X2201</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Atopic Dermatitis</healthcondition>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Dermatological conditions</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Other skin conditions</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - QAW039
Treatment: drugs - Placebo

Experimental: QAW039 - Participants received QAW039 450 mg daily by mouth.

Placebo Comparator: Placebo - Participants received matching placebo to QAW039.


Treatment: drugs: QAW039
Capsules

Treatment: drugs: Placebo
Capsules

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change From Baseline in Eczema Area and Severity Index (EASI) - Investigators assessed presence and severity of erythema, induration/papulation, excoriation, and lichenification in four body areas: head/neck (H), upper limbs (UL), trunk (T), and lower limbs (LL). Investigators assigned a severity score from 0 - 3 for each area (none=0, mild=1, moderate=2, and severe=3). Investigators could assign half-points. Investigators also assigned an area score from 0 (no atopic dermatitis lesion in the area) to 6 (entire area is affected) for each area. The weighting factor was 0.1 for head/neck, 0.2 for upper limbs, 0.3 for trunk, and 0.4 for lower limbs. The total body score for each body region was obtained by multiplying the sum of the severity scores of the four key signs by the area score, then multiplying the result by the constant weighted value assigned to that body region. The sum of these scores gave the EASI total, ranging from 0 to 72. A higher score represented greater disease severity. A negative change from baseline indicates improvement.</outcome>
      <timepoint>Baseline, 12 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in Eczema Area and Severity Index - Investigators assessed presence and severity of erythema, induration/papulation, excoriation, and lichenification in four body areas: head/neck (H), upper limbs (UL), trunk (T), and lower limbs (LL). Investigators assigned a severity score from 0 - 3 for each area (none=0, mild=1, moderate=2, and severe=3). Investigators could assign half-points. Investigators also assigned an area score from 0 (no atopic dermatitis lesion in the area) to 6 (entire area is affected) for each area. The weighting factor was 0.1 for head/neck, 0.2 for upper limbs, 0.3 for trunk, and 0.4 for lower limbs. The total body score for each body region was obtained by multiplying the sum of the severity scores of the four key signs by the area score, then multiplying the result by the constant weighted value assigned to that body region. The sum of these scores gave the EASI total, ranging from 0 to 72. A higher score represented greater disease severity. A negative change from baseline indicates improvement.</outcome>
      <timepoint>Baseline, 4 weeks, 8 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Key 

          -  Presence of atopic dermatitis confirmed by Itchy skin condition in the past 12 months
             plus three, or more, of the following:

               -  History of involvement of the skin creases (fronts of elbows, behind knees,
                  fronts of ankles, around neck or around eyes)

               -  Personal history of asthma or hay fever

               -  History of generally dry skin in the past year

               -  Onset before age of 2 years

               -  Visible flexural dermatitis

          -  Patients with an EASI score of =15 at screening and stable AD (not currently
             experiencing an acute flare of their AD).

          -  Patients that have been treated with topical corticosteroids or topical calcineurin
             inhibitors on at least one occasion, or could not use topical drugs (due to
             contraindications, side effects, etc.) and are candidates for or have previously
             received systemic treatment.

        Key</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  History of hypersensitivity to any of the study drugs (including local anesthesia) or
             to drugs of similar chemical classes (CRTh2 antagonists)

          -  History of serious allergic reactions to any allergen, such as anaphylactic shock or
             life-threatening asthma, prior intubation, respiratory arrest, hospitalization due to
             asthma within the last 3 months or seizures as a result of asthma

          -  History of clinically significant ECG abnormalities or screening/baseline ECG that
             demonstrated clinical significant abnormalities which could affect patient safety or
             interpretation of study results

          -  History of long QT syndrome or whose QTc interval (Frederica's) was prolonged (&gt;450
             msec for males and females) at screening

          -  Use of topical prescription treatment (e.g., topical corticosteroids, calcineurin
             inhibitors, antibiotics, etc.) within two weeks prior to initial dosing of study drug.
             Patient use of emollients was encouraged

          -  Exception: For local atopic dermatitis flares during this 2-week interval, mild
             topical corticosteroids may be taken short term (up to one week)

          -  Recent previous systemic treatment with phototherapy, systemic antihistamines,
             immunosuppressive agents (e.g., cyclosporine, mycophenolate, or oral tacrolimus,
             including therapeutic proteins)

          -  Patients on maintenance immunotherapy who either began their allergen specific
             immunotherapy regimen or had a clinically relevant change to their immunotherapy
             within one month prior to granting informed consent

          -  Patients on high-dose statin therapy (&gt;40 mg fluvastatin or 20 mg simvastatin,
             atorvastin, pravastatin, or rosuvastatin [10 mg if Asian])

          -  Excessive exposure to UV light in the three weeks prior to study start (screening),
             including tanning and sun beds and/or planning excessive sunbathing or beach holidays
             with associated sun bathing during the treatment period

          -  History of hypertrophic scarring

          -  Body mass index &lt;17 or &gt;40 kg/m2</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/06/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>103</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/11/2014</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>ACT,QLD</recruitmentstate>
    <hospital>Novartis Investigative Site - Phillip</hospital>
    <hospital>Novartis Investigative Site - Benowa</hospital>
    <hospital>Novartis Investigative Site - Woolloongabba</hospital>
    <postcode>2606 - Phillip</postcode>
    <postcode>4217 - Benowa</postcode>
    <postcode>4102 - Woolloongabba</postcode>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Vienna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Bruxelles</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Li√®ge</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Sofia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bonn</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Dresden</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Muenster</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Amsterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Groningen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Utrecht</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Bucharest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Durban</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Novartis Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine whether QAW039 is safe and has beneficial effects
      in people who have moderate to severe atopic dermatitis (AD).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01785602</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Novartis Pharmaceuticals</name>
      <address>Novartis Pharmaceuticals</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>